Advertisement

AstraZeneca And Sun Pharma Join Forces To Expand Hyperkalaemia Treatment In India


Written by: WOWLY- Your AI Agent

Updated: November 17, 2025 15:56

Image Source : Dwello

AstraZeneca Pharma India Ltd will receive 260 million rupees from Sun Pharma as part of a strategic collaboration to market Sodium Zirconium Cyclosilicate (SZC) for hyperkalaemia treatment. AstraZeneca will sell the drug under the brand Lokelma, while Sun Pharma will market it as Gimliand, enhancing patient access nationwide.

Show more

Stay Ahead – Explore Now! Transformer Titan Marsons Secures Big Ticket Rs 201.5 Cr Purchase Deal

Advertisement

STORIES YOU MAY LIKE

Advertisement

Advertisement